GlobeNewswire Inc | Nov 12, 2021 08:22AM EST

November 12, 2021

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

New data presented at 14th CTAD conference support ACI-35.030s advancement into late-stage development

LAUSANNE, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate being developed in partnership with Janssen Pharmaceuticals, Inc., at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference, which is being held in Boston, Massachusetts from November 9-12, 2021.

ACI-35.030 is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. At CTAD, AC Immunes Chief Medical Officer Johannes Streffer gave an on-demand oral presentation featuring data from an ongoing, placebo-controlled Phase 1b/2a trial evaluating ACI-35.030 in participants with early Alzheimers disease (AD). Results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments (ePHF).

Additional key findings from the CTAD presentation include:

-- Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030 -- Anti-ePHF IgG titers increased by one order of magnitude from baseline as early as two weeks after the second injection at week 8 of the mid-dose of ACI-35.030 -- The anti-ePHF IgG response was boosted following additional doses at weeks 8 and 24 -- The ACI-35.030-induced immune response was lasting over an initial period of 26-weeks and showed class-switching from IgM to IgG -- Interim safety data further support ACI-35.030s favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.

As previously announced, the ongoing Phase 1b/2a study has been expanded to include a total of 24 AD participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: To see such a strong and lasting immune response against a self-protein in an elderly population is both an exceptional finding and an important step towards shifting the AD treatment paradigm towards earlier treatment and prevention. Pathological pTau is present in the CSF as a precursor many years before Tau accumulation is detectable via imaging techniques. By developing ACI-35.030 while leveraging cutting edge Tau diagnostics, we aim to deliver on the significant promise this anti-pTau vaccine has shown as a potential early intervention for AD. We look forward to continuing our collaboration with Janssen Pharmaceuticals, Inc. and to reporting additional immunogenicity data from the Phase 1b/2a trials high-dose group.

Prof. Philip Scheltens, Professor of Neurology at Amsterdam UMC Alzheimer Center and Principal Investigator of the Phase 1b/2a study, commented: These promising results provide important preliminary data, and these findings may aid in dose selection for later stage investigation. This information will be invaluable as we work to further ACI-35.030s clinical development and ultimately fulfill the hopes of clinicians and patients for a therapy that could delay, or even prevent, the onset of AD.

About the SupraAntigen platformAC Immunes clinically validated SupraAntigen platform uses proprietary liposomes to rapidly generate novel vaccines (SupraAntigen-V) for active immunization as well as best-in-class monoclonal antibodies (SupraAntigen-A) for passive immunization against key neurodegenerative disease targets. Antibodies generated by the platform are highly specific for the pathological conformations of misfolded proteins and have shown strong safety. The SupraAntigen platform has successfully generated two vaccines and two antibody candidates that have been validated in clinical studies and has led to multiple global partnerships with world-leading pharmaceutical companies. In addition to targeting Amyloid-beta and Tau, AC Immune has generated conformation-specific antibodies against emerging neurodegenerative disease targets including alpha-synuclein, TDP-43 and the NLRP3 inflammasome pathway.

About the Phase 1b/2a pTau AD Vaccine TrialThe Phase 1b/2a study is a randomized, multicenter, double-blind, placebo-controlled clinical study with a primary objective to assess the safety, tolerability and immunogenicity of different dosages of ACI-35.030 and JACI-35.054 in participants with early AD. Secondary objectives will assess additional immunogenicity parameters, while exploratory endpoints will include notable biomarkers of progression of AD as well as clinical assessments. This Phase 1b/2a study evaluating ACI-35.030 and JACI-35.054 was initiated in Q3 2019 and is currently ongoing.

About AC Immune SA AC Immune SAis clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins. The Companys two clinically validated technology platforms, SupraAntigenand Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies includingGenentech, a member of the Roche Group, Eli Lilly and Company, andJanssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3billionin potential milestone payments.

SupraAntigenis a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU. Morphomeris a registered trademark ofAC Immune SAin CN, CH, GB, JP, and NO.

For further information, please contact:

Media Relations Investor RelationsSaoyuth Nidh Yves Kremer, Ph.D.AC Immune AC ImmunePhone: +41 21 345 91 34 Phone: +41 21 345 91 90Email: saoyuth.nidh@acimmune.com Email: yves.kremer@acimmune.com U.S. Media U.S. InvestorsShani Lewis Corey Davis, Ph.D.LaVoieHealthScience LifeSci AdvisorsPhone: +1 609 516 5761 Phone: +1 212 915 2577Email: slewis@lavoiehealthscience.com Email: cdavis@lifesciadvisors.com

Forward looking statementsThis press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key Information Risk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.